DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors
DaVita HealthCare (DVA) reached $236.97 at the closing of the latest trading day, reflecting a +1.26% change compared to its last close.
DVA - DaVita Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$239.50
DETAILS
HIGH:
$270.00
LOW:
$218.00
MEDIAN:
$235.00
CONSENSUS:
$239.50
UPSIDE:
1.07%
Stock News
DaVita HealthCare (DVA) Rises As Market Takes a Dip: Key Facts
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $234.01, denoting a +1.04% move from the preceding trading day.
DaVita: I Believe This Is Overvalued
DaVita Inc. has more than doubled in share price within six months, driven by a strong Q1 '26 beat and a favorable court ruling. DVA fundamentals and long-term prospects remain largely unchanged, with 2026E AEPS recovery now expected at 30%+ and 10–16% annualized growth through 2028. I sold over 95% of my DVA position as the valuation exceeded $210/share, far above my fair value target of $130/share.
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $232.8, denoting a +1.45% move from the preceding trading day.
Everyone Is Watching Greg Abel. But Another Berkshire Hathaway Stock Picker Is Quietly Winning in 2026.
Greg Abel may have taken over as CEO, but he's not the only one making key investment decisions at Berkshire Hathaway. Berkshire's positions in DaVita and SiriusXM, reportedly selected by Ted Weschler, who manages a portion of the portfolio, have outperformed so far in 2026.
DaVita HealthCare (DVA) Suffers a Larger Drop Than the General Market: Key Insights
DaVita HealthCare (DVA) reached $230.72 at the closing of the latest trading day, reflecting a -1.53% change compared to its last close.
Top 5 Non-AI S&P 500 Stock Picks for 2H 2026 That Have Surged in 1H
ADM, CASY, DVA, CVS and BEN top a list of five non-AI S&P 500 stocks that surged more than 30% in 1H 2026 and still show momentum for 2H.
DaVita Inc (DVA) Stock Up 3.0% but GF Value Says Overvalued -- GF Score: 88/100
On July 02, 2026, DaVita Inc (DVA) shares rose 3.0% to a current price of $234.91. The stock has experienced significant price appreciation recently, with a 10.
Should Value Investors Buy DaVita (DVA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Best Growth Stocks to Buy for July 2nd
DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 2, 2026.
DaVita Stock Benefits From Strengthening Kidney Care Delivery
DVA is advancing kidney care through IKC expansion, CMS CKCC progress and AI-driven dialysis scheduling improvements.
Best Growth Stocks to Buy for June 30th
DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 30, 2026.
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why the Market Dipped But DaVita HealthCare (DVA) Gained Today
In the most recent trading session, DaVita HealthCare (DVA) closed at $217.04, indicating a +1.72% shift from the previous trading day.
If You Own These 10 Stocks — Analysts Think You Should Sell Them
Analysts don't like to put "sell" ratings on S&P 500 stocks. So the fact they're willing to do it with some is worth your attention.
Best Growth Stocks to Buy for June 26th
LYB, HRB and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 26th, 2026.
DaVita HealthCare (DVA) Ascends While Market Falls: Some Facts to Note
The latest trading day saw DaVita HealthCare (DVA) settling at $213.04, representing a +1% change from its previous close.
DaVita Stock Benefits From Expanding Community-Based Kidney Care
DVA is expanding kidney care through outpatient, home-centered and value-based programs while investing in AI-enabled scheduling.
Best Growth Stocks to Buy for June 24th
HRB, DVA and PBI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 24th, 2026.
DVA vs. FMS: Which Dialysis Leader Is Better Positioned Now?
DaVita and Fresenius Medical Care are taking different paths in kidney care, but which stock offers stronger upside now? Let's dive in.
Price Targets
DaVita price target raised to $250 from $205 at Truist
$250.00
(was $235.58)
Truist Financial
DaVita price target raised to $270 from $235 at UBS
$270.00
(was $229.48)
UBS
DaVita price target raised to $218 from $194 at Barclays
$218.00
(was $234.31)
Barclays
DaVita price target raised to $205 from $158 at Truist
$205.00
(was $194.38)
Truist Financial
DaVita price target raised to $194 from $158 at Barclays
$194.00
(was $193.88)
Andrew Mok
·
Barclays
DaVita upgraded to Buy from Hold at Deutsche Bank
$220.00
(was $157.04)
Pito Chickering
·
Deutsche Bank
DaVita price target raised to $158 from $128 at Truist
$158.00
(was $144.41)
Truist Financial
DaVita price target raised to $190 from $186 at UBS
$190.00
(was $134.73)
UBS
DaVita price target raised to $158 from $143 at Barclays
$158.00
(was $111.19)
Barclays
DaVita price target lowered to $143 from $149 at Barclays
$143.00
(was $126.56)
Barclays
DaVita price target lowered to $140 from $148 at Truist
$140.00
(was $123.36)
David MacDonald
·
Truist Financial
DaVita price target lowered to $149 from $160 at Barclays
$149.00
(was $127.89)
Andrew Mok
·
Barclays
DaVita price target lowered to $148 from $164 at Truist
$148.00
(was $129.54)
David MacDonald
·
Truist Financial
Warren Buffett's Berkshire Hathaway Sells $116M Shares Of Dialysis Giant DaVita, Cuts Stake By 2%
$184.00
(was $142.40)
Lisa Bedell Clive
·
Bernstein
DaVita price target raised to $145 from $139 at BofA
$145.00
(was $133.53)
Kevin Fischbeck
·
Bank of America Securities
DaVita price target raised to $150 from $133 at Barclays
$150.00
(was $134.45)
Andrew Mok
·
Barclays
DaVita price target lowered to $81 from $103 at Barclays
$81.00
(was $70.54)
Sarah James
·
Barclays
UBS Assumes DaVita (DVA) with a Buy
$117.00
(was $93.10)
Andrew Mok
·
UBS
DaVita (DVA) Stock: $90 Target And Hold Rating
$90.00
(was $79.44)
David MacDonald
·
Truist Financial